Development of Multiple Antibiotic Resistance By Opportunistic Bacterial Pathogens During Human Space Flight (BRIC-18-1) - 08.05.15

Overview | Description | Applications | Operations | Results | Publications | Imagery

ISS Science for Everyone

Science Objectives for Everyone
The Biological Research in Canisters (BRIC) hardware supports a variety of biological investigations. The Development of Multiple Antibiotic Resistance By Opportunistic Bacterial Pathogens During Human Space Flight (BRIC-18-1) investigation tests the hypothesis that microgravity increases the development of simultaneous resistance to rifampicin (RIF) and trimethoprim (TMP), two antibiotics that are often prescribed together.
Science Results for Everyone
Information Pending

The following content was provided by Wayne L. Nicholson, and is maintained in a database by the ISS Program Science Office.
Experiment Details

OpNom: BRIC

Principal Investigator(s)
Wayne L. Nicholson, University of Florida - Space Life Sciences Laboratory, Merritt Island, FL, United States

Co-Investigator(s)/Collaborator(s)
Patricia Fajardo-Cavazos, University of Florida - Space Life Sciences Laboratory, Merritt Island, FL, United States
Ralf Moeller, German Aerospace Center (DLR), Cologne, Germany

Developer(s)
NASA Kennedy Space Center, Cape Canaveral, FL, United States

Sponsoring Space Agency
National Aeronautics and Space Administration (NASA)

Sponsoring Organization
Human Exploration and Operations Mission Directorate (HEOMD)

Research Benefits
Information Pending

ISS Expedition Duration
March 2014 - September 2014

Expeditions Assigned
39/40

Previous ISS Missions
Information Pending

^ back to top

Experiment Description

Research Overview

  • Maintaining crew member health during long-term spaceflight is of prime importance to the success of exploration missions to destinations such as the Moon, near-Earth asteroids, or Mars.
  • The immune system weakens during Low Earth Orbit missions, rendering crew members more susceptible to infection.
  • Microgravity has been shown to increase virulence and antibiotic resistance in certain bacterial species.
  • This investigation tests the effects of microgravity of the combination treatment of RIF and TMP antibiotics.

Description
Maintaining crew member health during long-term spaceflight is of prime importance to the success of exploration missions to destinations such as the Moon, near-Earth asteroids, or Mars. The immune system weakens during missions in Low Earth Orbit, rendering astronauts mores susceptible to infection. Microgravity induces in certain bacterial species increased virulence properties such as: adherence to mammalian cells, biofilm formation, resistance to acid and macrophages, and antibiotic resistance. As part of the normal population of microbial inhabitants on and within the human body, crew members carry many microbes considered “opportunistic pathogens”, i.e., normally harmless microbes with the potential to cause disease in hosts with lowered immune function. Opportunistic infections are often treated with combinations of two antibiotics that differ in their mechanisms of action. Combination treatment can be effective because (i) certain antibiotic combinations work synergistically to more effectively combat the pathogen than either drug given alone, and (ii) the probability of the pathogen evolving resistance to two antibiotics simultaneously is much lower than that of becoming resistant to a single antibiotic.
 

^ back to top

Applications

Space Applications
The BRIC-PDFU hardware provides the capability to conduct biological experiments and deliver fluids in one self-contained piece of hardware without the need for a glovebox.  This approach minimizes resources such as volume, mass and crew time. Understanding multidrug resistance in opportunistic pathogens during long-term human space flight directly benefits crew member health and the success of extended missions in both Low Earth Orbit and in interplanetary space.

Earth Applications
The types and amounts of antibiotics to be included on an extended human space mission are carefully selected for the predicted needs of the crew members long before the actual launch. Any factors altering a potential pathogen's susceptibility to the antibiotics available onboard could result in treatment failure and severely compromise the crew members' health. The results from this proposed study contribute to our knowledge concerning how antibiotic resistance arises in the space flight environment. This data aids the ongoing development of guidelines determining antibiotic use during long-term space flight.

^ back to top

Operations

Operational Requirements
Cells are transferred in dry statis and are activated 7 days after docking with a TSY+10% glycerol growth medium. After a 7 day growth period, the BRIC canisters are stored at -95°C in the MELFI until landing and handover. Frozen samples are planned for return on the same SpaceX mission as launched.

Operational Protocols
At 7 and 14 days after docking, the BRIC-18-1 payload hardware is accessed for activation. A rod is removed from the Rod Kit and inserted into the BRIC-PDFU Actuator Tool. The BRIC-PDFU Actuator Tool is attached to the selected BRIC-PDFU canister lid in position 1 and is used to mechanically force TSY+10% glycerol growth medium into the Petri dishes. The process is repeated until all the PDFUs are activated in both canisters. Seven days after activation, the BRIC canisters must be transferred to the MELFI for freezing of the samples at -80°C or less.

^ back to top

Results/More Information

^ back to top

Related Websites
University of Florida Faculty Website
Institute of Aerospace Medicine

^ back to top


Imagery

image BRIC Canister.
+ View Larger Image


image BRIC Actuator Tool and Rod.
+ View Larger Image


image Actuation of BRIC Canister.
+ View Larger Image